Paper
NJC
conjugate acid of a given base in water is provided in parentheses 131.4, 141.0, 147.6, 168.1, 169.2, 169.4, 170.2, 170.5, 172.5,
as follows: 2,6-di-tert-butylpyridine (3.58),48 1,10-phenanthroline 172.8, 173.2; ESI-MS obsd 665.1499, calcd 665.1492 [(M + H)+,
(4.96),67 2,6-lutidine (5.77),48 triethylamine (10.85),68 pempidine M = C28H29ClN4O13].
(1,2,2,6,6-pentamethylpiperidine, 11.25),69 and N,N-diisopropyl-
1-Acetyl-5-[(4-methoxy-6-morpholino-1,3,5-triazin-2-yl)oxy]-1H-
indol-3-yl 2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside (morph-13).
ethylamine (11.44).70
5-Hydroxy-1H-indol-3-yl b-D-glucopyranoside (10). A suspension A solution of 13 (10.0 mg, 0.015 mmol) and i-Pr2EtN (3.4 mL,
of 9 (917.4 mg, 1.50 mmol), having 499% stereochemical purity at 0.020 mmol) in CH2Cl2 (150 mL) at room temperature was treated
the anomeric carbon, in MeOH (7.50 mL) at room temperature was with morpholine (1.4 mL, 0.017 mmol). After 2 h, the reaction
treated with sodium methoxide (25 wt% solution in MeOH, mixture was quenched by the addition of AcOH (0.9 mL) and
648 mL, 3.0 mmol). After 2 h, acetic acid (229 mL, 6.00 mmol) directly purified by chromatography (silica, ethyl acetate) to
1
and Pd/C (10 wt%, 79.8 mg, 0.075 mmol) were added. The reaction afford a white solid (10.6 mg, 99%): H NMR (700 MHz, CDCl3)
mixture was stirred for 2 h under a H2 atmosphere (balloon) at d 2.05 (s, 3H), 2.06 (s, 3H), 2.08 (s, 3H), 2.10 (s, 3H), 2.61 (s, 3H),
room temperature and then filtered through a Celite pad. The 3.64–3.75 (m, 6H), 3.81–3.90 (m, 3H), 3.90 (s, 3H), 4.24
filtrate was concentrated and purified by chromatography [silica, (dd, J = 4.5, 12.1 Hz, 1H), 4.29 (dd, J = 2.3, 12.1 Hz, 1H), 5.00–
CH2Cl2/MeOH (7 : 3)] to afford a pale yellow solid (417.6 mg, 89%): 5.06 (m, 1H), 5.14–5.22 (m, 1H), 5.27–5.34 (m, 2H), 7.17 (d, J =
mp darkened 455 1C; 1H NMR [400 MHz, (CD3)2SO] d 3.09–3.29 2.4 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 7.27 (s, 1H), 8.40 (br s, 1H);
(m, 4H), 3.42–3.53 (m, 1H), 3.65–3.76 (m, 1H), 4.47–4.55 (m, 1H), 13C NMR (175 MHz, CDCl3) d 20.7, 20.8, 20.9, 24.0, 44.1, 44.2,
4.59 (br s, 1H), 5.07 (br s, 1H), 5.15 (br s, 1H), 5.38 (br s, 1H), 6.58 54.8, 62.0, 66.7, 66.7, 68.3, 71.1, 72.57, 72.59, 100.8, 110.5, 110.7,
(dd, J = 2.6, 8.6 Hz, 1H), 6.89 (d, J = 2.0 Hz, 1H), 6.98 (d, J = 2.6 Hz, 117.4, 120.8, 124.7, 131.2, 141.3, 148.6, 166.9, 168.2, 169.4, 169.5,
1H), 7.06 (d, J = 8.6 Hz, 1H), 8.68 (br s, 1H), 10.21 (s, 1H); 13C NMR 170.3, 170.7, 172.5, 172.7; ESI-MS obsd 716.2410, calcd 716.2410
(100 MHz, CD3OD) d 62.6, 71.5, 75.0, 78.02, 78.04, 102.5, 105.8, [(M + H)+, M = C32H37N5O14].
112.9, 113.1, 113.5, 121.9, 130.4, 138.4, 160.0; ESI-MS obsd
334.0894, calcd 334.0897 [(M + H)+, M = C14H17NO7].
5-{[4-({1-[(1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-yl]-3-oxo-2,7,10-
trioxa-4-azadodecan-12-yl}amino)-6-methoxy-1,3,5-triazin-2-yl]oxy}-
1-Acetyl-5-hydroxy-1H-indol-3-yl 2,3,4,6-tetra-O-acetyl-b-D-gluco- 1H-indol-3-yl b-D-glucopyranoside (15). A sample of 13 (20.3 mg,
pyranoside (11). A suspension of 9 (6.911 g, 11.3 mmol) and 0.0305 mmol) was added to a solution of (1R,8S,9s)-bicyclo-
Pd/C (10 wt%, 360.8 mg, 0.339 mmol) in ethyl acetate/EtOH [6.1.0]non-4-yn-9-ylmethanol (10.4 mg, 0.0321 mmol) and i-Pr2EtN
(4 : 1, 113 mL) was stirred for 3 h at room temperature under a (6.7 mL, 0.038 mmol) in CH2Cl2 (150 mL) at room temperature. After
H2 atmosphere (balloon). The reaction mixture was filtered 3 h, MeOH (750 mL) and K2CO3 (13.3 mg, 0.096 mmol) were added.
through a Celite pad. The filtrate was concentrated and purified After 1 h, the reaction mixture was quenched by the addition of
by chromatography [silica, CH2Cl2/ethyl acetate (10 : 1)] to afford acetic acid (9.2 mL) and then filtered. The filtrate was concentrated
a pale yellow solid (5.85 g, 99%): mp 88–90 1C; 1H NMR and purified by chromatography [silica, CH2Cl2/MeOH (3 : 1)] to
(400 MHz, CDCl3) d 2.05 (s, 3H), 2.06 (s, 3H), 2.09 (s, 3H), 2.12 afford a pale yellow solid (21.0 mg, 93%): 1H NMR (700 MHz,
(s, 3H), 2.56 (s, 3H), 3.77–3.88 (m, 1H), 4.23 (dd, J = 5.0, 12.4 Hz, CD3OD, B1 : 1 mixture of rotamers) d 0.85–0.98 (m, 2H), 1.25–1.40
1H), 4.93–5.03 (m, 1H), 5.11–5.23 (m, 1H), 5.23–5.34 (m, 2H), (m, 1H), 1.49–1.65 (m, 2H), 2.09–2.30 (m, 6H), 3.10–3.18 (m, 1H),
5.82–6.02 (m, 1H), 6.85–6.96 (m, 2H), 7.10 (br s, 1H), 8.22 3.23–3.28 (m, 1H), 3.29–3.63 (m, 14H), 3.716 (dd, J = 5.6, 11.9 Hz,
(br s, 1H); 13C NMR (100 MHz, CDCl3) d 20.63, 20.66, 20.73, 0.5H), 3.719 (dd, J = 5.7, 11.9 Hz, 0.5H), 3.87–3.93 (m, 2.5H), 3.94
20.8, 23.7, 62.1, 68.3, 71.1, 72.4, 72.6, 101.0, 103.2, 110.9, 115.1, (s, 1.5H), 4.10 (d, J = 8.1 Hz, 0.5H), 4.12 (d, J = 8.2 Hz, 0.5H), 4.68
117.7, 125.4, 128.3, 141.3, 153.0, 168.2, 169.58, 169.63, (d, J = 8.1 Hz, 0.5H), 4.70 (d, J = 8.1 Hz, 0.5H), 6.67–6.73
170.4, 171.0; ESI-MS obsd 544.1430, calcd 544.1426 [(M + Na)+, (m, 0.5H), 6.78–6.84 (m, 0.5H), 6.87 (dd, J = 2.3, 8.7 Hz, 1H),
M = C24H27NO12].
6.90 (dd, J = 2.3, 8.7 Hz, 1H), 7.17 (s, 1H), 7.28 (d, J = 8.7 Hz,
1-Acetyl-5-[(4-chloro-6-methoxy-1,3,5-triazin-2-yl)oxy]-1H-indol- 0.5H), 7.29 (d, J = 8.7 Hz, 0.5H), 7.47 (d, J = 2.3 Hz, 0.5H), 7.48
3-yl 2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside (13). A sample of (d, J = 2.3 Hz, 0.5H); 13C NMR (175 MHz, CD3OD, mixture of
i-Pr2EtN (65.3 mL, 0.375 mmol) was added dropwise over 5 min rotamers) d 18.9, 21.4, 21.9, 30.1, 41.2, 41.5, 41.6, 41.7, 41.9,
to a suspension of 11 (130.4 mg, 0.250 mmol) and 12 (58.5 mg, 55.2, 55.3, 62.6, 63.70, 63.74, 70.0, 70.3, 70.8, 70.88, 70.91, 71.16,
0.325 mmol) in CH2Cl2 (1.25 mL) at 0 1C. The reaction mixture 71.22, 71.5, 75.0, 78.0, 78.16, 78.19, 99.5, 105.9, 106.0, 110.8,
was allowed to warm to room temperature and stirred for 2 h. 111.0, 112.7, 112.9, 114.0, 114.2, 117.3, 117.5, 121.4, 121.5,
The reaction mixture was washed with aqueous citric acid 132.9, 133.0, 139.18, 139.24, 146.4, 146.6, 159.2, 159.2, 169.3,
(10%, 1 mL) followed by brine (1 mL), then dried (Na2SO4) 169.5, 173.4, 173.7, 173.9, 174.1; ESI-MS obsd 743.3249, calcd
and filtered. The filtrate was concentrated and purified by 743.3247 [(M + H)+, M = C35H46N6O12].
chromatography [silica, hexanes/ethyl acetate (2 : 3)] to afford
5-[((Benzylcarbamoyl)oxy)]-1H-indol-3-yl b-D-glucopyranoside
a white solid (188.3 mg, 87%): 1H NMR (300 MHz, CDCl3) d 2.05 (16). Samples of p-nitrophenyl chloroformate (6.0 mg, 0.029 mmol)
(s, 3H), 2.06 (s, 3H), 2.09 (s, 3H), 2.10 (s, 3H), 2.62 (s, 3H), 3.80– and i-Pr2EtN (6 mL, 0.03 mmol) were added to a solution of 11
3.95 (m, 1H), 4.02 (s, 3H), 4.14–4.38 (m, 2H), 4.97–5.09 (m, 1H), (13.0 mg, 0.025 mmol) in CH2Cl2 (1 mL) at room temperature.
5.09–5.40 (m, 3H), 7.10–7.36 (m, 3H), 8.44 (br s, 1H); 13C NMR After 1 h, the reaction mixture was quenched by the addition
(175 MHz, CDCl3) d 20.6, 20.68, 20.71, 23.8, 56.3, 61.9, 68.2, of saturated aqueous NH4Cl (2 mL) and stirred for 30 min at
70.9, 72.37, 72.43, 100.7, 110.2, 111.1, 117.7, 119.7, 124.8, room temperature. Water (2 mL) was added, and then the
New J. Chem.
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2019